|
1
|
Initial genome sequencing and analysis of multiple myeloma.
|
Nature
|
2011
|
17.28
|
|
2
|
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
|
Cell
|
2011
|
14.34
|
|
3
|
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
|
Cancer Cell
|
2007
|
7.24
|
|
4
|
Multiple myeloma: evolving genetic events and host interactions.
|
Nat Rev Cancer
|
2002
|
5.30
|
|
5
|
Genetics and cytogenetics of multiple myeloma: a workshop report.
|
Cancer Res
|
2004
|
4.54
|
|
6
|
Clonal competition with alternating dominance in multiple myeloma.
|
Blood
|
2012
|
4.39
|
|
7
|
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.
|
Nat Immunol
|
2008
|
4.33
|
|
8
|
Advances in biology of multiple myeloma: clinical applications.
|
Blood
|
2004
|
4.13
|
|
9
|
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
|
Blood
|
2011
|
3.58
|
|
10
|
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
|
Cancer Cell
|
2004
|
3.55
|
|
11
|
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
|
Blood
|
2006
|
3.39
|
|
12
|
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.
|
Nature
|
2011
|
3.10
|
|
13
|
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
|
Blood
|
2011
|
3.07
|
|
14
|
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
|
Blood
|
2012
|
2.98
|
|
15
|
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
|
Mayo Clin Proc
|
2009
|
2.86
|
|
16
|
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.
|
Cancer Cell
|
2008
|
2.84
|
|
17
|
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
|
Mayo Clin Proc
|
2013
|
2.59
|
|
18
|
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
|
Blood
|
2007
|
2.58
|
|
19
|
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
|
Cancer Cell
|
2007
|
2.56
|
|
20
|
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
|
Mayo Clin Proc
|
2007
|
2.55
|
|
21
|
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
|
J Clin Oncol
|
2009
|
2.50
|
|
22
|
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
|
Blood
|
2011
|
2.45
|
|
23
|
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
|
Mayo Clin Proc
|
2007
|
2.34
|
|
24
|
Molecular pathogenesis of multiple myeloma and its premalignant precursor.
|
J Clin Invest
|
2012
|
2.24
|
|
25
|
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
|
Cancer Res
|
2007
|
2.19
|
|
26
|
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
|
Blood
|
2011
|
2.13
|
|
27
|
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
|
Blood
|
2009
|
2.12
|
|
28
|
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
|
Blood
|
2012
|
2.07
|
|
29
|
Characterization of MYC translocations in multiple myeloma cell lines.
|
J Natl Cancer Inst Monogr
|
2008
|
2.01
|
|
30
|
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.
|
Blood
|
2010
|
1.96
|
|
31
|
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
|
Blood
|
2012
|
1.88
|
|
32
|
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
|
Blood
|
2009
|
1.86
|
|
33
|
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
|
Blood
|
2005
|
1.81
|
|
34
|
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
|
J Clin Oncol
|
2010
|
1.77
|
|
35
|
Approach to the treatment of multiple myeloma: a clash of philosophies.
|
Blood
|
2011
|
1.57
|
|
36
|
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
|
Cancer Res
|
2009
|
1.57
|
|
37
|
Prognostic factors in multiple myeloma: it's in the genes.
|
Clin Cancer Res
|
2003
|
1.55
|
|
38
|
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
|
Blood
|
2004
|
1.49
|
|
39
|
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.
|
Blood
|
2009
|
1.44
|
|
40
|
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
|
Mayo Clin Proc
|
2010
|
1.34
|
|
41
|
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
|
Mayo Clin Proc
|
2010
|
1.32
|
|
42
|
IMWG consensus on maintenance therapy in multiple myeloma.
|
Blood
|
2012
|
1.29
|
|
43
|
Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model.
|
Proc Natl Acad Sci U S A
|
2010
|
1.25
|
|
44
|
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
|
J Clin Invest
|
2008
|
1.22
|
|
45
|
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
|
Am J Hematol
|
2011
|
1.11
|
|
46
|
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
|
PLoS One
|
2011
|
1.10
|
|
47
|
Smoldering multiple myeloma requiring treatment: time for a new definition?
|
Blood
|
2013
|
1.09
|
|
48
|
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
|
Blood
|
2012
|
1.09
|
|
49
|
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
|
Int J Hematol
|
2013
|
1.04
|
|
50
|
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
|
J Immunol
|
2011
|
1.01
|
|
51
|
Many multiple myelomas: making more of the molecular mayhem.
|
Hematology Am Soc Hematol Educ Program
|
2011
|
1.00
|
|
52
|
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
|
PLoS Genet
|
2011
|
0.99
|
|
53
|
Early genetic events provide the basis for a clinical classification of multiple myeloma.
|
Hematology Am Soc Hematol Educ Program
|
2005
|
0.98
|
|
54
|
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma.
|
Mol Cancer Ther
|
2007
|
0.97
|
|
55
|
MYC addiction: a potential therapeutic target in MM.
|
Blood
|
2012
|
0.96
|
|
56
|
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.
|
Blood
|
2013
|
0.95
|
|
57
|
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
|
Blood
|
2006
|
0.91
|
|
58
|
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
|
Am J Hematol
|
2014
|
0.89
|
|
59
|
The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
|
Curr Opin Hematol
|
2002
|
0.89
|
|
60
|
Advances in biology and therapy of multiple myeloma.
|
Hematology Am Soc Hematol Educ Program
|
2003
|
0.89
|
|
61
|
Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.
|
Cancer Res
|
2009
|
0.86
|
|
62
|
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
|
J Clin Invest
|
2015
|
0.86
|
|
63
|
Bone lesions in molecular subtypes of multiple myeloma.
|
N Engl J Med
|
2004
|
0.86
|
|
64
|
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
|
Br J Haematol
|
2015
|
0.85
|
|
65
|
Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications.
|
Blood
|
2008
|
0.85
|
|
66
|
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
|
Br J Haematol
|
2014
|
0.83
|
|
67
|
Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma.
|
Cancer Cell
|
2010
|
0.81
|
|
68
|
Osteopontin dysregulation and lytic bone lesions in multiple myeloma.
|
Hematol Oncol
|
2007
|
0.81
|
|
69
|
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
70
|
WSU-WM and BCWM.1 should not be assumed to represent Waldenström macroglobulinemia cell lines.
|
Blood
|
2008
|
0.78
|
|
71
|
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
|
Haematologica
|
2011
|
0.78
|
|
72
|
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
|
J Clin Invest
|
2015
|
0.78
|